LONDON (Alliance News) - Scancell Holdings PLC on Thursday said it has closed the patient recruitment process for the SCIB1 immunobody clinical trial in patients with stage 3 or 4 melanoma.
The last patient in the formal six month study will be dosed in October this year after which the company will analyse the data and prepare a clinical study report. Patients on long-term continuation treatment will continue to be dosed for up to five years from the start of their treatment regime, Scancell said.
As with previously reported data, SCIB1 continues to be a safe and well-tolerated treatment with no withdrawals from the study due to drug-related adverse events, it added.
"With the recruitment of the SCIB1 Phase 1/2 melanoma trial coming to a close, we continue to see highly encouraging survival times and melanoma-specific immune responses in patients, especially those with resected tumours," said Richard Goodfellow, Scancell's joint chief executive.
Shares in Scancell were down 0.9% to 27.5 pence in early trade on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)